Conditional knockdown of hepatic PCSK9 ameliorates high-fat diet-induced liver inflammation in mice
InstructionAccumulating evidence has shown that proprotein convertase subtilisin/kexin type 9 (PCSK9) is associated with inflammation in the vascular system. However, the roles of PCSK9 in hepatic inflammation remain unclear. Because PCSK9 is mainly expressed in the liver and modulates lipid uptake...
Saved in:
Main Authors: | Xue-Ying Zhang, Qing-Qing Lu, Yan-Jie Li, Shan-Rui Shi, Chao-Nan Ma, Miao Miao, Shou-Dong Guo |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2025-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1528250/full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01) -
Mutual mediation effects of homocysteine and PCSK9 on coronary lesion severity in patients with acute coronary syndrome: interplay with inflammatory and lipid markers
by: Ping Jin, et al.
Published: (2025-01-01) -
Efficacy and safety of PCSK9 inhibitors, potent statins, and their combinations for reducing low-density lipoprotein cholesterol in hyperlipidemia patients: a systematic network meta-analysis
by: Yuhua Jiang, et al.
Published: (2025-02-01) -
The relationship between oxLDL, sLOX-1, PCSK9 and carotid intima-media thickness in patients with prediabetes and type 2 diabetes
by: Zeki Dogan, et al.
Published: (2025-02-01) -
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)